The history of TCTAP is a history of unceasing change and evolution. In order to provide high quality research and scientific resources, as well as professional interactions for the advancement of science, TCTAP has been trying to keep up with innovation. For almost two decades it has been growing both in academic quality of higher education and in size by draws thousands of attendees. TCTAP attracts researchers and practitioners from academic, public, and private sectors from 50 different countries to Seoul every April and about half of the total reported attendees come from outside Korea.

As the leading name representing interventional therapy, TCTAP2014 continues to expand its scientific collaboration with global partners. It is expected to help fulfill the mission to facilitate research, education, and collaboration with global partners to benefit worldwide. Prominent interventional cardiologists in each country get involved in planning and designing sessions for the purpose of introducing and sharing their current techniques, systems, and best practices to audiences with different backgrounds and cultures. The organization was very pleased with the positive feedback for 2013, but also carefully evaluated the comments, recommendations, and suggestions. As a result, we implemented some new topics and various workshops this year and brought together experts from all around the world to re-present different views and perspectives. We hope all of you enjoy our active, and dynamic learning environment at TCTAP2014.

This year, newly expanded partnership sessions were organized by 11 international societies and groups from the Asia-Pacific region and USA.

(Highlights from Yesterday)

Fellowship Training Course

TCTAP continues to grow and evolve, emulating the field of interventional cardiology itself. This year, the TCTAP Fellowship Course broadened the reach of angioplasty from left main & bifurcation PCI to endovascular intervention. The sessions took place from 10:00 AM to 4:30 PM on Tuesday with great attention by fellows and young cardiologists. The courses, which were divided into themes, featured lectures by specialists as well as answered questions that enable attendees to assess their current knowledge.

(TCTAP 2014-Gear Up for the Next Innovation)

The 19th TCTAP started with CTO LIVE 2014 yesterday. The CTO LIVE 2014 was held successfully with more than five hundred attendees including physicians, technologists, nurses, and medical professionals. CTO LIVE had pre-intervention case reviews, expert’s lecture, featured lecture, and case wrap-up sessions to provoke enthusiasm and provide updated anagre and retrograde wire strategy of CTO-PCI, new devices, and current data in CTO-PCI. After 7 successful live demonstrations, all operators shared their experiences and explained their techniques and tips during the procedure in detail. Our featured lecture session emphasized the role of current new-generation DES including Bioabsorbable Vascular Scaffold (BVS) in CTO-PCI. Recently, CTO lesions have become a possible target for PCI in proper patients but required a special skill set and understanding of anatomy, imaging, and dedicated devices. We hope that leading or beginning interventional cardiologists become familiar with CTO intervention through our CTO LIVE demonstration.

(Continued on page 7)

Inside

Today’s Programs page 3
Imaging and Physiology Summit page 4
8th CTO LIVE 2014 page 9
DES Summit page 11
Fellowship Course & Partnership Session page 12
Endovascular Symposium page 15

excellence for life

At BIOTRONIK, we are proud to know our long-standing, unsurpassed record of quality is an achievement our physicians and patients trust in and depend upon.

Verena Hari, Production DEx

www.biotronik.com
**Meeting Information**

- **Registration / Badge Pick-up**
  - 3F, Exhibition Hall Lobby
  - Wednesday 23 - Thursday 24: 6:00 AM - 7:00 PM
  - 1F, Grand Ballroom Lobby
  - Friday 25: 6:00 AM - 12:30 PM

- **Conference Bag Pick-up**
  - 3F, Exhibition Hall Lobby
  - Wednesday 23: 6:00 AM - 7:00 PM
  - Thursday 24: 6:00 AM - 7:00 PM
  - 1F, Lobby
  - Friday 25: 6:00 AM - 12:30 PM

- **Invited Faculty Lounge, 2F**
  - Wednesday 23: 6:00 AM - 7:00 PM
  - Thursday 24: 6:00 AM - 7:00 PM
  - Friday 25: 6:00 AM - 12:30 PM

- **Preview Room, 2F (Slide Upload)**
  - Wednesday 23: 6:00 AM - 7:00 PM
  - Thursday 24: 6:00 AM - 7:00 PM
  - Friday 25: 6:00 AM - 12:30 PM

- **CVRF Booth, 1F (Organizing Secretariat)**
  - Wednesday 23: 6:00 AM - 7:00 PM
  - Thursday 24: 6:00 AM - 7:00 PM
  - Friday 25: 6:00 AM - 12:30 PM

- **Information Desk**
  - 3F, Main Arena Lobby
  - 1F, CVRF Booth

- **Tour Information Desk**
  - 1F, CVRF Booth

- **Lounge**
  - 3F, Exhibition Hall, Registration
  - 1F, CVRF Booth

- **Exhibition, 3F**
  - Wednesday 23: 9:00 AM - 6:00 PM
  - Thursday 24: 9:00 AM - 6:00 PM

- **Learning Center**
  - 3F, Exhibition Hall
  - 2F, Room 2-5 (Room 209)

- **WiFi Zone**
  - 3F, Exhibition Hall, Main Arena, Registration Lounge
  - 2F, Invited Faculty Lounge, Preview Room
  - 1F, CVRF Booth, Coronary Arena, Structural Heart & Endovascular Theater

- **Cyber Station**
  - 3F, Exhibition Hall
  - 1F, CVRF Booth

- **Free Mobile Recharge**
  - 3F, Exhibition Hall, Registration Lounge
  - 1F, CVRF Booth

- **Certificate of Attendance**
  - 3F, Service Booth
  - Wednesday 23 - Thursday 24: 6:00 AM - 7:00 PM
  - 1F, Service Booth
  - Friday 25

- **Lost & Found / Cloak Room**
  - 3F, Coat Room
  - Wednesday 23 - Thursday 24: 8:00 AM - 6:00 PM

- **Shuttle Bus**
  - Free shuttle bus is provided between COEX and several venue hotels. Ask at the CVRF booth, 1F or Information desk, 3F for more information.

- **Prayer Room**
  - 2F, Room 202A
  - Wednesday 23 - Thursday 24: 8:00 AM - 6:00 PM
  - Friday 25: 8:00 AM - 12:00 PM

---

**TCTAP Daily News**

---

**TCTAP Wrap-up Interview**

Moderated interview sessions at the open studio Main Arena Lobby, Level 3 on selected key topics in the field of vascular medicine with world’s leading experts

**Wednesday, April 23**

**Renal Stenting Controversy** (9:00 AM - 9:30 AM)
Moderator: Krishna Rocha-Singh

**CTO** (9:50 AM - 10:20 AM)
Moderator: Etsuo Tsuchikane
Interviewees: Yves R. Louvard, Toshiya Muramatsu

**STEMI Intervention** (11:00 AM - 11:30 AM)
Moderator: Stephen G. Ellis
Interviewees: Bernard Chevalier, Cindy L. Grines, Neal S. Kleiman

**FFR** (11:50 AM - 12:20 PM)
Moderator: John McB. Hodgson
Interviewees: Eric Van Belte, William F. Fearon, Seung-jung Park

**TAVI** (5:15 PM - 5:45 PM)
Moderator: Alain G. Cribier
Interviewees: Eberhard Grube, Martin B. Leon, Ian T. Meredith

**Thursday, April 24**

**Invasive Imaging** (8:45 AM - 9:15 AM)
Moderator: Gary S. Mintz
Interviewees: Takashi Akasaka, Akiko Maehara, Evelyn Regar

**Antithrombotic Therapies** (9:30 PM - 10:00 PM)
Moderator: David J. Cohen
Interviewees: Jean-Philippe Collet, Neal S. Kleiman, Manesh Patel

**LM and Bifurcation** (3:45 PM - 4:15 PM)
Moderator: David E. Kandzari
Interviewees: Yves R. Louvard, Seung-jung Park, David Paul Taggart

*Interview video clips will be available online after the meeting at www.summit-tctap.com, www.summitmd.com and www.youtube.com/CVRFevents*

---

**TCTAP Application**

---

*We cordially invite you to*

**ACT Tour @ Asan Medical Center**

**Program**
Live Case Demonstration, Presentation and Q&A
Tour of Cathlab, CCU and Other Facilities

**Schedule**
Tour 1: April 23(Wed) at 4 PM
Tour 2: April 24(Thu) at 10 AM
Tour 3: April 24(Thu) at 4 PM
*Each tour will be limited up to 12 people.*

**Pick-up Place**
ACT Desk at CVRF Booth, 1F Lobby, COEX
*Onsite registration is available.*

For more information, visit www.cvrf.org/act
## Today’s Programs: Wednesday, April 23

### Plenary Sessions
- **8:30 AM - 6:00 PM**
  - **Main Arena, Level 3**

#### Live Case Session I - USA
- Transmitted from Columbia University Medical Center, USA
- **8:30 AM - 9:30 AM**

#### Main Session I. Opening of TCTAP 2014
- **9:30 AM - 9:48 AM**

#### Main Session II. TCTAP Award 2014
- **9:48 AM - 10:00 AM**

#### Main Session III. TCT Session @TCTAP 2014: Hot Topics and Featured Lectures
- **10:00 AM - 12:30 PM**

#### Main Session IV
- **10:00 AM - 11:30 AM**
  - **Room 1-2, Level 1**
  - **Coronary Arena, Level 1**

#### Hot Topics and Featured Lectures
- **9:30 AM - 9:48 AM**

#### Coronary Symposium
- **7:30 AM - 2:00 PM**
  - **Main Arena, Level 3**

#### Imaging & Physiology Summit
- **2:00 PM - 5:30 PM**

#### DES Summit
- **3:30 PM - 5:30 PM**

#### Chien Foundation Award for Outstanding Lectureship & Lifetime Achievement in PCI
- **5:55 PM - 6:00 PM**

### Endovascular Symposium
- **10:00 AM - 11:30 AM / 2:00 PM - 6:00 PM**
  - **Endovascular & Structural Heart Theater, Level 1**

#### Live Case Session I
- **10:00 AM - 11:30 AM**

#### Endovascular Session I. Complex PCI
- **2:00 PM - 3:00 PM**

#### Live Case Session II
- **3:00 PM - 4:00 PM**

#### Endovascular Session II. SFA Intervention
- **4:00 PM - 5:00 PM**

#### Live Case Session III. Below the Knee Intervention
- **5:00 PM - 6:00 PM**

### Partnership Session with International Society
- **2:00 PM - 6:00 PM**
  - **Room 1-2, Level 1**

#### CCT Session @TCTAP 2014: Improve Success of CTO PCI
- **2:00 PM - 4:00 PM**

#### CIT Session @ TCTAP 2014: Optimization of Left Main PCI in "Real World" Practice
- **4:00 PM - 6:00 PM**

### Morning Roundtable Forum: Meet the Experts over Breakfast
- **7:00 AM - 8:10 AM**

#### STEMI Intervention: Unresolved Issues & Future
- Organized by CVRF
  - **Room 1-1, Level 1**

#### Functional Angioplasty
- Organized by CVRF and Supported by Educational Grant from St. Jude Medical
  - **Room 1-2, Level 1**

#### Chronic Total Occlusion
- Organized by CVRF and Supported by Educational Grant from ASAH INTECC (AMG Korea)
  - **Coronary Arena, Level 1**

#### Lesson from TAVI Cases
- Organized by CVRF and Supported by Educational Grant from Edwards Lifesciences Korea
  - **Coronary Arena, Level 1**

#### Drug-Eluting Stents: Bioabsorbable Vascular Scaffolds
- Organized by CVRF and Supported by Educational Grant from Abbott Vascular
  - **Room 1-3, Level 1**

#### BTK Intervention: Share Breath with Expert
- Organized by CVRF and Supported by Educational Grant from Medtronic Co., Ltd.
  - **Room 2-1, Level 2**

### Lunchtime Activities
- **12:45 PM - 1:45 PM**

#### How Can We Improve Personalized Medicine?
- A Close Look at Diabetes and Primary PCI
  - Organized by CVRF and Supported by Educational Grant from BIOTRONIK
  - **Room 1-1, Level 1**

#### Contemporary Stent Designs: How to Customize it to Make it Better?
- Organized by CVRF and Supported by Educational Grant from Boston Scientific
  - **Room 1-2, Level 1**

#### DEB: Treat with All Possibility and Preserve Future Option
- Organized by CVRF and Supported by Educational Grant from Medtronic Co., Ltd.
  - **Endovascular & Structural Heart Theater, Level 1**

- **11:30 AM - 12:30 PM**
  - **No meals to be served**

### Evening Symposium
- **6:00 PM - 7:00 PM**

#### Oral Antiplatelet Agents in ACS Management
- Organized by CVRF and Supported by Educational Grant from Astrazeneca Korea
  - **6:00 PM - 8:20 PM**
  - **Room 1-1, Level 1**

#### Pulmonary Arterial Hypertension and Congenital Heart Disease: Role of Interventional Cardiology
- Organized by CVRF and Supported by Educational Grant from Handok
  - **6:00 PM - 8:20 PM**
  - **Endovascular & Structural Heart Theater, Level 1**

### New Tech Symposium Co-sponsored by Abbott Vascular
- **6:00 PM - 8:30 PM**
  - **Room 1-3, Level 1**

### Live Case Transmission from World-renowned Medical Centers

- **Asan Medical Center, Seoul, Korea**
  - **April 23 - 24**
  - **Main Arena, Level 3 / Endovascular & Structural Heart Theater, Level 1**

- **Columbia University Medical Center, New York, USA**
  - **April 23, 8:30 AM - 9:30 AM, Main Arena, Level 3**
  - **Operator: Jeffrey W. Moses MD, Rebecca Hahn MD, Dimitrios Karpapliotis MD, Susheel Kodali MD, Matthew Williams MD**

- **St. Paul Hospital, Vancouver, Canada**
  - **April 24, 8:30 AM - 9:30 AM, Main Arena, Level 3**
  - **Operator: John Webb MD, David Wood MD**

- **Institut Hospitalier Jacques Cartier, Paris, France**
  - **April 24, 3:30 PM - 4:30 PM, Main Arena, Level 3**
  - **Operator: Marie-Claude Morice MD, Thomas Hovasse MD**

---

**TCTAP Daily News / Wednesday 23th April, 2014 / Seoul**
IVUS guided PCI for Better PCI Outcome

In the afternoon session of Imaging and Physiology Summit, Dr. Akiko Maehara (CRF, New York, USA) will present about the advantage of IVUS-guided PCI based on the ADAPT-DES IVUS substudy. IVUS has provided valuable information on cross-sectional coronary vascular structure and has played a key role in contemporary stent-based PCI by accurately assessing coronary anatomy, assisting in selection of treatment strategy, and defining optimal stenting outcomes. In the bare-metal stent era, randomized trials and meta-analysis demonstrated that IVUS-guided PCI was mainly associated with a lower risk of angiographic restenosis and target vessel revascularization. In the drug-eluting stent (DES) era, a recent meta-analysis showed that the risk of death and stent thrombosis was reduced by IVUS-guided DES implantation.

ADAPT DES was a prospective, multicenter, nonrandomized “all-comers” study of 8,583 consecutive patients at 11 international centers designed to determine the frequency, timing, and correlates of stent thrombosis and adverse clinical events after DES. As a prespecified subgroup analysis, Dr. Maehara evaluated the IVUS guided PCI versus angiography guided PCI. In this large observational study, she found that IVUS was utilized in 3,349 patients (39%) and larger-diameter devices, longer stents, and/or higher inflation pressures were used in 74% of IVUS-guided cases. IVUS guidance compared with angiography guidance was associated with reduced 1-year rates of definite/probable stent thrombosis (0.6% [18 events] versus 1.0% [53 events]; adjusted hazard ratio, 0.40; 95% confidence interval, 0.21-0.73; P=0.003), myocardial infarction (2.5% versus 3.7%; adjusted hazard ratio, 0.66; 95% confidence interval, 0.49-0.88; P=0.004), and composite adjudicated major adverse cardiac events (ie, cardiac death, myocardial infarction, or stent thrombosis) (3.1% versus 4.7%; adjusted hazard ratio, 0.70; 95% confidence interval, 0.55-0.88; P=0.002) (Figure 1). The benefits of IVUS were especially evident in patients with acute coronary syndromes and complex lesions, although significant reductions in major adverse cardiac events were present in all patient subgroups including those with stable angina and single-vessel disease. Therefore, IVUS guidance was associated with a reduction in stent thrombosis, myocardial infarction, and major adverse cardiac events within 1 year after DES implantation.

NIR Spectroscopy: Fundamentals and Diagnostic Applications

Dr. Akiko Maehara (CRF, New York, USA) will present the basics and the clinical applications of NIR Spectroscopy, very sensitive intracoronary imaging to detect lipid core plaque (Figure 2). Near-infrared spectroscopy (NIRS) provides information about the composition of tissue by measuring the absorption of light over a range of wavelengths. It is particularly useful in detecting lipid core plaques, which are a major contributor to cardiovascular disease. NIRS can be used to identify vulnerable plaques that are at high risk for rupture and subsequent thrombosis.

Figure 1.

Continued on page 5
spectroscopy takes advantage of the fact that different substances absorb and scatter NIR light (wavelengths from 800 to 2,500 nm) to different degrees at various wavelengths. An NIR spectrometer emits light into a sample and measures the proportion of light that is returned over a wide range of optical wavelengths. The return signal is then plotted as a graph of absorbance (y-axis) at different wavelengths (x-axis) called a spectrum. Dr. Maehara will point out the clinical benefit of NIR Spectroscopy as follows: 1) the prediction of periprocedural myocardial infarction due to distal embolization after PCI 2) the detection of vulnerable plaque at the risk of future myocardial infarction 3) potential improvement of PCI outcomes.

**FFR guided PCI in Routine Practice: the Experience of Asan Medical Center**

In the session of assessment of myocardial ischemia, several world renown “functionalists” will present the benefit of FFR measurement based on large registry data. Firstly, Dr. Seung-Jung Park (Asan Medical Center, Korea) will present the experience of the Asan Medical Center. He will mention that during the past 30 years, percutaneous coronary intervention (PCI) has become one of the standard treatment strategies for patients with ischemic heart disease since successful PCI of ischemia-producing stenoses reduced cardiovascular events. However, in a significant proportion of patients, PCI is performed without documentation of ischemia, which is not beneficial and is instead associated with increasing clinical risks and economic costs. Fractional flow reserve (FFR) is a pressure-wire-based index used during invasive procedure to identify ischemia-producing coronary stenoses. The accuracy of FFR has been validated in a wide variety of clinical and anatomic situations. Moreover, several randomized and observational studies have documented the benefit of using FFR to select coronary stenoses for stent implantation. Although contemporary guidelines recommend FFR measurements in the absence of clinical evidence of ischemia, the use of FFR during coronary intervention is reported to be only 6%. Many operators still use angiography to decide if and when to perform revascularization. In addition, there are limited large studies that reproduce the benefits of FFR in real world practice. The ASAN PCI registry is composed of two distinct periods separated by the introduction of mandated routine FFR use. The use of FFR in this prospective registry has increased from 1.9% between 2008 and 2009 to 50.7% between 2010 and 2011. This rapid adaptation of FFR within a relatively brief time frame provided a valuable opportunity to evaluate the overall benefit of FFR-guided PCI in real practice. Here, we report the changes in practice and outcomes of patients who underwent PCI before and after the routine use of FFR. Between January 2008 and December 2011, 5,097 patients underwent PCI at an academic hospital in Korea. We used propensity-score matching to compare the rates of the primary endpoint (death from any causes, myocardial infarction, or repeat revascularization) between patients at 1 year before and after the routine use of FFR. The rate of FFR use during PCI significantly increased from 1.9% to 50.7% after the introduction of routine FFR use (P<0.001). FFR was successfully measured in 1,267 patients; of those, PCI was deferred in 475 (37.5%) without any stent implantation. The number of lesions per patient was 1.8 ± 0.9 before versus 1.8 ± 1.0 after the routine FFR use (P = 0.39). The total number of stents implanted per patient was 2.1 ± 1.3 versus 1.5 ± 1.2, respectively (P<0.001). In the propensity-score matched cohort (2,178 pairs), the rates of the primary endpoint was significantly lower in patients after the routine use of FFR.

**Today’s Hot Lives**

**Q** How would you treat this lesion involving LM tri-furcation? After treating this lesion, would you like to fix the remaining lesion in LAD, high OM, and LCX? If you hesitated to put a stent depending on only an angiography, what modality would help your decision-making?

**Q** Would you like to stent the LCX in treating LM bifurcation lesion? If you would, which technique would you prefer to stent this lesion with?
Xience Xpedition™
Everolimus Eluting Coronary Stent System

Smooth
The most agile XIENCE. Ever.
XIENCE Safety • Smooth Tracking

www.AbbottVascular.com
©2013 Abbott. All rights reserved. KR CP0001-EN 01/13
tine FFR use versus patients before the routine use of FFR (hazard ratio, 0.55; 95% confidence interval, 0.43–0.70, \( P < 0.001 \)). This was primarily due to a reduction in periprocedural myocardial infarction and repeat revascularization. Routine measurement of FFR in daily practice appeared to be associated with fewer use of stents and an improvement in clinical outcomes.

**FFR Together with Coronary Angiography: Insights from a Large French Registry**

Eric Van Belle (Hôpital Cardiologique, France) will present registry data. He will say that although recent data suggest that FFR can be useful in guiding coronary revascularization in patients referred for a PCI procedure (DEFER, FAME, FAME2), its benefit in patients referred for diagnostic angiography remains unclear. The present report investigated the role of FFR on the choice of treatment modalities in 1,075 patients referred for diagnostic angiography in 20 French centers. It first demonstrates that the use of FFR changes marginally the proportion of patients referred to each treatment modality. The “strategy a priori” based on angiography was medical therapy in 55% and revascularization in 45% (PCI=38%, CABG=7%). The applied strategy after FFR was medical therapy in 58% and revascularization in 42% (PCI=52%, CABG=10%). It further demonstrates that the use of FFR is associated with “reclassification” of the initial treatment modality in 43% of cases: in 33% of “a-priori”-medical patients, in 56% of “a-priori”-PCI patients and in 62% of “a-priori”-CABG patients. Finally it shows that “reclassification” by FFR (n=464) is associated with a MACE rate of 11.2% and a proportion of patients free of angina (94%) at one-year similar to patients in whom FFR results concurred with the angiography-based decision. He will conclude that performing FFR during diagnostic angiography is associated with reclassification of the treatment modality in about half of the patients. He will comment on the concept of “physiology guided” coronary revascularization and will provide important basis for future studies.

**FFR-CT**

Charles Taylor from the HeartFlow company will talk about the FFRCT. Non-invasive CT-derived computed FFR (FFRCT) is a novel technology that enables non-invasive assessment of the functional significance of lesions from computational fluid dynamics (CFD) applied to coronary computed tomography angiography (cCTA). The scientific principles that underlie this technology are as follows: a three-dimensional patient specific anatomic model is first constructed from the cCTA data followed by physiologic modeling, the basal coronary outlet resistances at rest are determined from myocardial mass and the vessel size at each outlet, the hyperemic condition is simulated by use of the experimental results that quantified the effect of adenosine; finally, CFD analysis is performed to numerically solve the governing equations of fluid dynamics.

Three prospective multicenter clinical studies have been conducted to evaluate the diagnostic performance of FFRCT. In these trials, FFRCT was demonstrated as superior to cCTA stenosis severity-based diagnosis. Since FFRCT technology enabled non-invasive methods to model patient specific coronary geometry and physiology, this technology can be also utilized in other clinical applications. Virtual intervention can provide guidelines to determine the optimal strategy for treating complex lesions before the invasive procedure. In addition, this technology is applicable to the analysis of hemodynamic parameters related with plaque progression and rupture. FFRCT necessitates accurate anatomic geometries and physiologic boundary conditions for subsequent CFD analysis. Thus, cCTA imaging artifacts may influence its accuracy. Additionally, average population-based physiologic model assumptions may limit accuracy as well.

**CT Myocardial Perfusion Imaging: One-Stop Shop for Structure and Function**

Dr. Young-Hak Kim (Asan Medical Center, Korea) will speak about computed tomography myocardial imaging. He will say that computed tomography myocardial perfusion imaging (CTP) has emerged as a method for the detection of myocardial ischemia and a potential advantage of CTP is the ability to provide three-dimensional imaging dataset covering whole heart with high spatial resolution (Figure 5). He analyzed the data of Asan Medical Center CTP registry. 197 symptomatic patients (mean 63.1 years; 126 male) who underwent combined CTP and coronary CT angiography (CTA) using second generation dual-source CT (retropective ECG-gating) were enrolled prospectively. Of them, 73 patients who underwent coronary angiography and FFR assessment in 210 epicardial arteries were enrolled in the primary analysis to test the diagnostic accuracy of CTP compared with FFR. FFR ≤ 0.8 after hyperemia was considered to indicate significant myocardial ischemia. Quantitative parameter for CTA analysis including transmural perfusion ratio (TPR), myocardial density, and myocardial perfusion reserve index were explored. Prevalence of ischemic territory was 41% (86/210) in FFR. Per-vessel sensitivity and specificity of CTP were 80%/95% in all patients, 87%/100% in patient with high coronary calcium score (CAC), and 75%/90% in multivessel disease patients. Specificity of CTP dropped significantly in patient with high CAC and multivessel disease (sensitivity/specificity: 99%/73% in all patients, 100%/50% in high CAC patients, and 100%/50% in multivessel disease patients, respectively). TPR showed moderate diagnostic accuracy (area under curve 0.78, cut-off 0.98) and combined use of quantitative parameters showed a potential to improve sensitivity of visual analysis of CTP. Mean radiation dose for CTP and CTA was 6.6 and 6.0 mSv, respectively. He will conclude that stress myocardial CTP is an accurate method for the identification of inducible ischemia in patients with suspected coronary artery disease. In patients with high CAC and multivessel disease in whom CTA shows low specificity, CTP may provide an incremental value for the prediction of myocardial ischemia.
ExoSeal™

2nd GENERATION Vascular Closure Device

Less complication,
More cost-effectiveness

- True Extravascular Closure
- Bioabsorbable Plug
- Secure Plug Placement with Fascia and Tissue Contraction

Fascia Layer
Arteriotomy

COPY-13003-CS

Cordis
Interview with Dr. Kenya Nasu (Toyohashi Heart Center, Japan): Retrograde approach has definitely improved the total procedural success rate of percutaneous coronary intervention (PCI) for coronary chronic total occlusion (CTO). On the other hand, lower success rate in antegrade approach remains one of the significant issues even in the retrograde approach era because antegrade technique, mainly guidewiring in CTO site, is also needed after wire crossing in collateral channels. For the improvement of the success rate in antegrade approach, new concept of guidewire control, “active wire control”, with new CTO guide wires is introduced as a new weapon to CTO PCI. In order to perform active wire control, the mechanisms of wire control must be understood. The CTO wire control has not been historically conceptualized. Only two mechanisms enable the active wire control in an occluded segment. The first is the torque control based on ideal torque response and the second is control of the tip deflection based on the interaction between the wire tip and the tissue contacting the wire tip. Basically, the wire deflection is triggered by two major factors: tip curve and difference in compliance between bordering tissues which means wire deflection is triggered at the border of tissues (Fig.1). Although direction control of wire advancement can be achieved only by deflection control, the torque control, which means controlling the direction of the tip curve, is indispensable to controlling wire deflection. An operator can delicately control wire deflection and therefore control the direction of wire advancement by minimizing the deflection. To minimize the deflection, the direction of the tip curve should be frequently changed, which requires sufficient torque control. To control the direction of the wire, it is simply pushed to direct the tip curve in the direction to be turned in order to make the deflection.

GAIA (Asahi Intec, Japan) is the newest guidewire for CTO lesion and has a completely different concept compared with conventional CTO guidewires to perform active wire control. GAIA has ideal performance, however, only an operator who understands the concept of active wire control can provide ideal performance.

Current Data and Strategy for DES in CTO
Dr. Sunao Nakamura (New Tokyo Hospital, Japan) talked about current data and strategy for DES in CTO yesterday. For the past 20 years since PCI was introduced for treatment of coronary artery, in Japan much effort has been made for recanilalization of CTO lesions which was regarded as the toughest challenge. Such effort raised the success ratio of the procedure from lower than 60% at the very beginning to almost 90% in 10 years. Furthermore, in 2003 an innovative new device was introduced. Drug Eluting Stent (DES) resolved chronic in-stent restenosis which has been the long-suffered challenges of PCI. His group presented CTO PCI...
results of patients treated with various DES at AHA in 2012 (Fig 2). Their chronic restenosis rate was lower than 10% in any type of DES, which clearly shows that PCI on CTO lesion can bring satisfactory results. Additional technical innovation such as the retrograde approach and reverse controlled antegrade and retrograde subintimal tracking (CART) technique was brought about which raised PCI success ratio close to 100%. What is noteworthy is that the technical development of retrograde approach and reverse CART technique that tore down the fortress of CTO PCI which used to be the world of master, opened up as a general practice. Thus CTO lesion is now included as a possible target of PCI. Recently another revolutionary development was seen in guidewires which brought the success of CTO PCI with simple antegrade approach. It can be said that PCI on CTO is now getting into the matured era. New technique and innovative devices brings high acute phase success rate. DES realizes extremely low chronic phase restenosis rate. All of these elements make CTO PCI highly reliable.

New Paradigm of CTO-PCI

Interview with Dr. Masahiko Ochiai (Showa University Northern Yokohama Hospital, Japan):

After redefining the CTO pathology (intimal and subintimal spaces) and reconfirming the importance of intimal wiring especially in antegrade PCI, Japanese interventional cardiologists and industry professionals accomplished a couple of breakthroughs in devices and strategies of CTO PCI. At first in devices, Gaia wire families became available in 2013. Gaia families have the same double coil structure as Sion. They have excellent torque control and strong penetration force with flexible tips. When the wire tip is directed towards sub-intimal space or is not strong enough to penetrate hard tissue in intimal space, these wires deflect easily. If I find this phenomenon, I change the wire direction thanks to its 1:1 torque response and try again to keep it straight to pass through intimal space. In other words, tactile feelings are now translated into visual perception. A Crusade dual lumen catheter has been used in bifurcation PCI for many years. Recently, this device is found to be quite useful in CTO PCI too. Yes, CTO is frequently located at bifurcation, which is quite natural considering its pathophysiology. If you find even a small side branch close to CTO, I recommend you to put a

Figure 3.

Moderated Poster Abstract Competition Session on April 22

Starting from this year, the Poster Abstract Session was held as a half-day program on the first day of TCTAP 2014 and was specially moderated by the distinguished experts of the field. Numbers of interesting abstracts were displayed as posters and orally presented by each author along with interactive discussion and Q & A between presenters and participants. In total, 5 best poster abstracts were selected by moderators at the end of the session and prized with honor. Here are the glorious winners of Best Poster Abstract 2014.

Best Poster Presenter

Session 1
Dr. Kevin Kien Hong Quah

Session 2
Dr. Jiang Ming Fam

Session 3
Dr. Costantino R. F. Costantini

Session 4
Dr. Kenji Sadamatsu

Session 5
Dr. William KF Kong

Continued on page 11
Wednesday, April 23, 4:30 PM - 5:55 PM, Coronary Arena, Level 1

What’s new in DES Summit 2014?

Wednesday, April 23, 4:30 PM - 5:55 PM, Coronary Arena, Level 1

Vascular Responses of Contemporary DES: Same or Different to First-Generation DES?

In the DES Summit 2014, Dr. Renu Virmani (CVPath Institute, Inc.) will present a very important topic regarding vascular response of contemporary DES.

Percutaneous coronary interventions involving stenting, particularly with drug-eluting stents (DES), are the most widely performed procedures for the treatment of symptomatic coronary disease; however, concerns still exist about the long-term safety of DES technology. Pathologic studies have identified delayed arterial healing with poor strut coverage as the primary substrate responsible for late and very late stent thrombosis (LST/VLST) following the first generation DES placement, whereas recent human autopsy studies have demonstrated that the second generation everolimus-eluting stents (EES) exhibit greater strut coverage with less inflammation, less fibrin deposition. However, the safety and efficacy of the fully biodegradable vascular scaffolds need to be investigated in large clinical trials involving patients with complex atherosclerotic lesions.

This lecture will suggest valuable pathologic information to develop newer generation DES with more safe and efficacious profile in the near future.

How Long DAPT Now and Future?

The most important clinical issue in the DES era is regarding optimal duration of dual antiplatelet therapy (DAPT), which is crucial for balancing bleeding and ischemic events. Dr. Cheol Whan Lee (Asan Medical Center, Korea) will present and will summarize a recent update of optimal duration of DAPT after DES implantation. The DES substantially reduces the risk of restenosis and the need for repeat revascularization compared with bare-metal stents. However, there has also been concern about the risk of late stent thrombosis after DES implantation. After the safety and efficacy of these devices were extensively investigated, it was suggested that prolonged dual antiplatelet therapy (DAPT) should be given for at least 12 months after DES implantation. However, this recommendation was largely based on registry data.

There have been several randomized controlled trials that compare short- versus long-term durations of DAPT in patients receiving DES. The EXCELLENT, the PRODIGY, and the RESET trials tested different durations of DAPT after implantation of DES, showing that short-term DAPT is not inferior to long-term DAPT. However, these trials were relatively small and underpowered to detect significant differences in hard clinical outcomes. The DES LATE trial compared the effect of 12 months versus > 12 months of DAPT in a relatively large number of patients who had received DES. The two treatment strategies did not differ in terms of the primary endpoint (death from cardiac causes, myocardial infarction, or stroke) with a potential risk of major bleeding. These findings support the notion that the benefits of DAPT after implantation of DES may not extend beyond 12 months. Currently, a large-scale DAPT (Dual Antiplatelet Therapy Study) trial is ongoing to address questions about the appropriate duration of DAPT in patients who have received DES. At present, the current guidelines recommend that DAPT should be given either for 6–12 months or at least 12 months after DES implantation unless patients are at high-risk for bleeding. However, long-term DAPT certainly increases the risk of bleeding complications, requiring a delicate balance between anti-ischemic benefits and bleeding risks.

DES technology has rapidly advanced over the past decade and late stent thrombosis may be less of a clinical issue with the use of new-generation DES. A marked risk reduction for very late stent thrombosis with everolimus-eluting stent compared with previous DES (sirolimus- or paclitaxel-eluting stents) was observed in a large registry of 12,339 consecutive patients. Furthermore, new-generation DES have been shown to be even safer than bare-metal stents. It has been shown that the risk of stent thrombosis after DES implantation is not a linear function of time. Stent thrombosis mostly occurs within 1 month after DES implantation and then rarely 3 months after the index procedure. Previous DES is no longer used in routine clinical practice and therefore the issue of whether a longer duration of DAPT is warranted in the current DES era requires further study. There is a growing body of evidence that continuation of DAPT beyond 6-12 months is not beneficial in patients treated with DES. Recently, the OPTIMIZE trial demonstrated that in patients with stable coronary artery disease or low-risk acute coronary syndrome treated with zotarolimus-eluting stents, 3 months of DAPT was noninferior to 12 months for major adverse cardiac events, without significantly increasing the risk of stent thrombosis. These findings suggest that the duration of DAPT can be further shortened in patients treated with new generation DES. However, further studies may be needed to determine optimal duration of DAPT in the era of new-generation DES.
Evolving from Left Main PCI to Endovascular Intervention

Fellowship Training Course

Tuesday, April 22, 10:00 AM – 4:30 PM, Coronary Arena, Level 1

TCTAP continues to grow and evolve, expanding the role of interventionality in the field of interventional cardiology itself. This year, TCTAP fellowship course broadened the reach of angioplasty from left main and bifurcation PCI to endovascular intervention. The sessions took place from 10:00 AM to 4:30 PM on Tuesday with great attention by fellows and young cardiologists. The courses, which were divided into themes, feature lectures by specialist as well as answered questions that enable attendees to assess their current knowledge.

Left Main & Bifurcation PCI
Seung-jung Park, MD, PhD (Asan Medical Center, Korea), served as guiding lights as interventional cardiologists designed the course of Left main and bifurcation PCI. Dr. Michael S. Lee presented various tips about selection of guiding catheter and angiography interpretation. Dr. Soo-jin Kang provided valuable lessons of invasive imaging tools in LM PCI. A number of recent meta-analyses have begun to shed light on some outstanding questions with regard to DES. Dr. Seung-jung Park showed the result of meta-analysis of LM PCI using DES vs CABG. Dr. Corrado Tamburino presented the importance of risk stratification for left main revascularization. Jacques J. Koolen presented practical tips and techniques about 2-stent strategy including minicrush, crush, culotte and TAP. Dr. Bon-Kwon Koo showed the utility of FFR and IVUS in non-LM bifurcation PCI. Dr. Joo-Yong Hahn presented the Know-how to predict and prevent side branch occlusion.

Imaging & Physiology
In the Imaging and Physiology Session, Akiko Maehara presented the role of IVUS for pre- and post-intervention. Young-Hak Kim introduced “CT-Perfusion” as the new diagnostic performance of noninvasive fractional flow reserve (FFR) derived from standard acquired coronary computed tomography for the diagnosis of myocardial ischemia. Gary S. Mintz presented the concept of next generation invasive imaging. Takashi Akasaka presented the role of OCT for pre- and post-intervention. Gary S. Mintz introduced Near-Infrared Spectroscopy (NIRS) and its clinical application.

Endovascular Intervention
In the Endovascular Intervention Session, Dr. Piotr Odrowaz-Pieniazek presented personal tips and tricks about carotid stenting. John Robert Laird provided important lessons for the EVAR including selection of patient, technical tips, and management of patient. Dr. Richard R. Heuser lectured about “lower extremity intervention.” Krishna Rocha-Singh showed the current evidence for management about renal artery stenosis. Fellowship training course was a unique opportunity for attendees to listen to lectures reviewing established knowledge as well as discussion of techniques and guidelines. “We plan to feature information that will help young cardiologist and vascular interventionists understand where we are going,” said Dr. Seung-jung Park.

Partnership Session with International Societies

This year, increased numbers of international societies and meetings play an active role in organizing international partnership sessions for TCTAP2014. Please see below session description of some of the participating groups.

Cardiological Society of India (CSI)
This year, CSI is undertaking the session “Momentary Lapse of Reason - Mortality Session.” The most dreaded nightmare in the cath lab is undoubtedly one with a fatal outcome. Unfortunately, anybody who really has a significant volume of PCI has faced this scenario, however skilled he / she may be. But, there is a tendency to brush them under the carpet. Thus, these cases are never discussed in any forum or any conference except the mortality session. These are the very cases where there is maximum opportunity to learn. Fortunately, as we end the old order and usher into a new era, there are individuals who are not afraid to be wrong, who are not afraid to own up to a responsibility (rather than thrust it upon somebody), who are willing to learn from their and others mistakes, and who are able to troubleshoot without being judgmental. It is keeping in mind these courageous physicians who possess strength of character that we have designed this session. Herein, we were able not only to discuss what went wrong (whether it was a wrong selection of case, wrong selection of hardware or technique), but also where exactly did it go wrong and finally what could have been done to salvage the situation, if at all possible.

Sundeep Mishra, MD
Hong Kong Society of Transcatheter Endocardiovascular Therapeutics (HKSTENT)
With the same enthusiasm and passion, we are pleased to co-organize a Partnership Session HKSTENT at TCTAP 2014 with CVRF. The session included a Physiology & Imaging Forum: From Risk Stratification to PCI optimization. Renowned experts were invited to deliver lectures on CT-FFR and iFFR and the ways to optimize PCI result with IVUS and OCT. We selected 3 cases to be presented in the Best of CICF 2014 session. International experts were invited to discuss various techniques to manage the complications. It was another educational and interactive session.

Li Wah Tam, MD
Taiwan Transcatheter Therapeutics (TTI)
The success rate of percutaneous coronary intervention (PCI) has improved much in the past decade through the sophistication of PCI skills and the availability of various devices. It is our pleasure to have a partnership with TCTAP2014. The experts from Taiwan Society of Cardiovascular Interventions (TSCI) presented their tricks in performing difficult cases of chronic total occlusion (CTO). You received first-glance image on these cases from their titles: an unusual way of retrograde wiring before rotablation, application of home-made loop snare in RCA-CTO intervention, double-guiding catheters in RCA CTO revascularization, and rescuing acute complication in LAD CTO intervention. These cases received the Best Awards in 2014 TTT (Taiwan Transcatheter Therapeutics) and will attract your interest in tackling tough CTO cases. The second part of TSCI joint symposium introduced the devices in facilitating the PCI procedures including when and how to use Guideliner, Crusade catheter, the tips in implementation of two stents technique in true bifurcation lesions, and finally presenting several complex left main lesion PCI cases. The presenters are experienced hands from different high-volume PCI centers in Taiwan and chairpersons joined the
Discussion to make this symposium more informative to the audience of TCTAP2014. The session was co-chaired by Immediate Past President of TSCI Prof. Jun-Jack Cheng at Shin-Kong Wu Ho-Su Memorial Hospital and newly elected President Prof. Juey-Jen Hwang at National Taiwan University Hospital and their colleagues.

Juey-Jen Hwang, MD

**Bangla Interventional Therapeutics (BIT)**

TCTAP 2014 offers an opportunity to present the works done currently in the international session, exchange views, and share experiences in the global context. The quality of the BIT at TCTAP 2014 scientific session was outstanding and covered the latest updates and interesting cases. Cases like multivessels angioplasty in post CABG patient, complex multivessels PCI, management of spontaneous dissection of left main, LAD, LCX after guide catheter engagement, double jeopardy catheterization lab disaster, complex left main bifurcation intervention, intervention of totally occluded renal artery, in-stent restenosis of proximal LAD in place of previous case, IVUS guided critical left main stem angioplasty, and battle against atherosclerosis, etc. were presented.

Actually this session was the first joint collaboration between TCTAP and BIT and hopes to ensure more vibrant symbiosis in future.

Afzalur Rahman, MD

**Indonesian Society of Interventional Cardiology (ISICAM)**

In the last few years, the Indonesian Society of Interventional Cardiology (ISIC) had routinely participated in International Joint Session in TCTAP. In our session we share our cases and discussed them with local and international panelists and audiences in the established TCTAP event. We believe that every country has unique cases and experiences often not encountered in other places and by sharing them with our colleagues we all could learn something new to provide better management plan for our patients. Ten interesting cases were presented in the field of coronary, peripheral, and structural cases in this session.

I also would like to remind all participants that ISIC, under the collaboration of Asia-Pacific Society of Interventional Cardiology (APSIC), will host The 10th Asian Interventional Cardiovascular Therapeutics (10th AICT) 2014 in Jakarta-Indonesia, from 27 – 29 November 2014 at the Ritz Carlton Hotel. The theme of this coming event is “Implementing Global vision to regional strategy to achieve optimal Cardiovascular Intervention outcome.” This annual event is an excellent opportunity to further strengthen our collaboration among cardiovascular interventionists and related industry in the Asia-Pacific region, a continuously growing area where we all are facing similar challenges and problems.

We will devote our utmost efforts to provide a rich scientific environment for learning, sharing and also to build networking in Asia-Pacific Intervention field. You will find your participation meaningful and memorable.

Doni Firman, MD
While having strong affiliations with international academic groups over the years, TCTAP has expanded the partnership sessions and especially this year, there will be highlights sessions co-organized by the Complex Cardiovascular Therapeutics (CCT) group and the China Interventional Therapeutics (CIT) group.

The CCT Session entitled “Improve Success of CTO PCI,” chaired by renowned Japanese and Korean CTO experts including Satoru Otsuji, MD of Higashi Takarazuka Satoh Hospital, Kinzo Ueda, MD of Rakuwakai Marutamachi Hospital and Etsuo Tsuchikane, MD of Toyohashi Heart Center, will feature lectures on preparation for CTO PCI and techniques to improve antegrade success, and case presentations will be given by Japanese CTO specialists to provide practical learning tips for daily practice.

The CIT Session, which newly joined as one of the partnership sessions, will feature an array of eminent experts in the field from around the world and cover essential lectures and case presentations on the topic of “Optimization of Left Main PCI in ‘Real World’ Practice” under the leadership by Shuzheng Lu, MD of Beijing Anzhen Hospital and Bo Xu, Director of Catheterization Lab of Cardiovascular Institute and Fu Wai Hospital. Attendees will experience various and in-depth specialized programs of each international society and TCTAP will continuously strengthen and expand these academic exchanges and collaboration as the leading interventional cardiology meeting, representing the Asia-Pacific region.

Dr. Spencer B. King III (Emory University School of Medicine, USA) was selected for the 6th Chien Foundation Award for Outstanding Lectureship & Lifetime Achievement in PCI at TCTAP2014. The presentation of this honored award will take place on April 23(Wed) at the Coronary Arena, Level 1, at 6:00 pm.

Dr. Spencer King is a pioneer in cardiac catheterization and coronary arteriography. He was also co-developer of the multi-purpose technique of coronary arteriography and has directed invasive and interventional cardiology training. Dr. King served as Director of the Cardiac Catheterization Laboratory of Emory University Hospital from its inception through 2000 and was Director of Interventional Cardiology and the Andreas Greuntzig Cardiovascular Center at Emory University from 1985 until 2000. Dr. King is also author of over 500 papers on cardiology, has edited or co-edited ten books including Interventional Cardiology and Hurst's The Heart 12th Edition both published in 2007. He is Editor-in-Chief of the Journal of the American College of Cardiology: Cardiovascular Intervention, is associate editor of JACC and is on the editorial board of seven other journals including Circulation. He has served as principal investigator or member of the steering committees of 15 national and international clinical trials in cardiology, as well as conducting the first NHLBI trial of coronary angioplasty versus bypass surgery.
Endovascular Symposium

More Interest and More Debate: Lower Extremity

Wednesday, April 23, 2:00 PM – 6:00 PM, Endovascular & Structural Heart Theater, Level 1

There remains a myriad of technologies available to treat either occlusive or stenotic lesions in the lower extremity. These technologies include simple angioplasty to stenting and further to drug coated balloon technologies. Alternatively, debulking strategies are also approved for this anatomic indication. Regardless of technology, what is clear is that the treatment of symptomatic lower limb atherosclerosis has become primarily endovascular. What remains unclear is does any one device have the “gold” standard designation and why?

**Superficial Femoral Artery: Which One is Better?**

Lawrence A. Garcia MD., Ph.D. (Tufts University School of Medicine, Boston, USA) briefly will review the current data results and suggest the role of atherectomy device in nettlestone lesion. When we review the data set for stenting in the SFA we are met with what is unfortunately, relatively short non-real world lesions that have little impact on the practice of medicine every day. What these trials have done are simply to allow an indication for the device in the United States—RESILIENT (LL 5.7cm), Zilver PTX (LL3.3cm), SUPERB (8.1cm). When we infer the data for our patients with lengthy lesions (LL5.3cm), SUPERB (8.1cm). When we infer these trials have done are simply to allow an indication for the device in the United States—RESILIENT (LL 5.7cm), Zilver PTX (LL3.3cm), SUPERB (8.1cm). When we infer these trials have done are simply to allow an indication for the device in the United States—RESILIENT (LL 5.7cm), Zilver PTX (LL3.3cm), SUPERB (8.1cm).

**Below The Knee: More Device and Which Strategy**

Massimiliano Fusaro, MD.,Ph.D. (Deutsches Herzzentrum, Munich, Germany) will present the value of DEB and DES in below-the-knee intervention. Patients suffering from atherosclerotic disease of below-the-knee (BTK) arteries represent an important challenge due to compromised functional status, coexisting morbidities, and poor outcomes. The guideline writing authorities recommend that in association with the management of baseline risk factors and comorbid conditions, endovascular therapy (EVT) should be preferred over surgery in patients with BTK atherosclerotic disease requiring revascularization. Endovascular revascularization has become a first-line treatment option in patients with symptomatic BTK disease, by virtue of the superior feasibility and the similar efficacy as compared to surgery. The limb salvage is the primary indication for endovascular treatment. Indeed, there is increasing evidence to support endovascular therapy in this setting if it can ensure a straight-line flow to the foot in at least one BTK artery. EVT falls under the broad category of minimally invasive surgery, making it more attractive to patients. The main advantages of EVT are the possibility to treat a multilevel disease with low complica-
tions. Furthermore, patients with failed conduits after surgery can be feasibly treated with endovascular therapy with significant improvement in terms of limb salvage rates. This latter represents a reasonable indication for endovascular therapy especially in those patients with poor target vessels, conduits, or exceeding surgical risk, as typical in patients suffering critical limb ischemia (CLI) due to BTK disease.

Osamu Iida, MD.,Ph.D. (Kansai Rosai Hospital Cardiovascular Center, Japan) will present about the impact of angiosome-oriented revascularization on clinical outcomes in patients with critical limb ischemia without concurrent wound infection and diabetes mellitus. In real situation, intervention-\alists have concerns about which artery or how many arteries must be opened during procedure for limb salvage. Use of the angiosome concept is associated with satisfactory clinical outcomes in revascularization of patients with CLI, apparently being more clinically efficacious and meaningful in EVT than in bypass surgery (BSX). BSX provides rapid and sufficient blood flow to the wound as well as long-term durability, however, angiosome-based BSX impacts wound healing.
Hypertensive patients need TWYNSTA

- The powerful blood pressure reductions needed to get patients to goal.¹
- Blood pressure reduction that lasts for a full 24 hours.²
- Contains Telmisartan - the only ARB with a cardiovascular protection indication (monotherapy).³⁴

only while other outcomes such as major limb amputation are unaffected. Less-invasive EVT alone does not achieve similar satisfactory levels of blood flow and durability as BSX, however, angiosome-based EVT impacts major clinical outcomes including incidence of major limb amputation and major adverse limb event (MALE) as well as amputation-free survival (AFS). Our study reported that in patients presenting with concurrent diabetes and wound infection, indirect endovascular revascularization (IR) resulted in poorer limb prognoses than direct revascularization (DR). However, CLI patients with both concurrent diabetes and wound infection constitute a minority population in the clinical setting and it remained undefined whether the same is true, specifically for complete wound healing and amputation-free survival (AFS), in patients other than those with both diabetes and wound infection. In this study, we examined the impact of angiosome-oriented revascularization on clinical outcomes including wound healing and AFS in CLI patients with isolated infrapopliteal lesions excluding those with both diabetes and wound infection. The analysis for the current study was based on data extracted from a multicenter database of 555 consecutive CLI patients, with ischemic tissue loss (i.e., Rutherford class 5 or 6) due to isolated infrapopliteal lesions, who had none or either, but not both diabetes mellitus and wound infection. Outcome measures including complete wound healing, amputation-free survival (AFS), and freedom from MALE (major adverse limb event) were compared between direct and indirect revascularization. To minimize differences in baseline characteristics, propensity matching analysis was performed and matched data were analyzed. Complete wound healing rate was 72±3% in the direct revascularization (DR) group versus 61±4% in the indirect revascularization (IR) group at 12 months (p=0.02). The median time to wound healing was 176 days (95% CI: 115 to 237 days) in the IR group and 110 days (95% CI: 71 to 149 days) in the DR group. AFS and freedom from MALE were assessed for up to 4 years as shown in Figures 3 and 4. AFS (74±3% vs. 70±3% at four years, P=0.17) and freedom from MALE (59±4% vs. 58±4% at four years, P=0.89) were not significantly different between the DR and IR groups. Therefore, we concluded that after propensity matching analysis for CLI patients other than those with both diabetes and wound infection, wound healing rate was statistically higher in the DR group than in the IR group, whereas AFS and MALE were not significantly different.
Gyeongbokgung Palace

Gyeongbokgung It was built three years after the Joseon Dynasty was founded and it served as its main palace. With Mount Bugaksan as a backdrop and the Street of Six Ministries (today’s Sejongno) outside Gwanghwamun Gate, the main entrance to the palace, Gyeongbokgung was situated in the heart of the Korean capital city.

Please visit Tour Information Desk, Level 1, for more information.
Simplify the Challenge.

- Most deliverable DES*
- Powerful clinical performance across the patient spectrum†
- First and only DES FDA-approved for patients with diabetes

Simplify the challenge at medtronicstents.com

*Based on bench test data on file at Medtronic, Inc.
†Per the Resolute Integrity™ Instructions for Use.